Design, Formulation Development and Characterization of Empagliflozin Nanosuspension
Abstract
To develop empaglifazon nanosuspension by Solvent evaporation technique using ethanol as organic phase then aqueous phase was prepared by dissolving acetate cellulose in water then add poloxamer-188 and sodium lauryl sulphate. Physicochemical properties like melting point, solubility, particle size and shape, in-vitro diffusion studies etc. were performed for the prepared nanosuspension formulations. Based on drug excipient compatibility studies such as FTIR images shown that there is no interaction between drug and excipients. XRD studies revealed the crystalline structure of the formulation. A surface characteristic was determined by SEM. In-vitro diffusion studies were carried out by Franz diffusion cell, found the ranges around 95% for both pure and optimized formulations. Research indicates that the Empagliflozin nanosuspension is optimal for prolonged and extended release. This nanosuspension has been found to effectively reduce diabetes mellitus when taken orally.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.